Candidate patients for cardiac surgery procedures with a history of malignancies and antitumour therapy or with an active cancer and on antineoplastic treatment are increasingly common in daily practice. Oncological therapy can lead to cardiovascular injury and, therefore, has the potential for impacting operative risks and surgical strategies. This means that a number of considerations are essential to take into account prior to cardiac surgery. These include the type of cancer, previous cardiotoxicity or concomitant antitumour therapy, reversibility or irreversibility of such complications, the interaction between cancer disease course and extracorporeal circulation, the need for associated surgery and the impact of cancer on early and long-term outcomes. Adequate preoperative evaluation of cardiovascular abnormalities potentially related to antineoplastic therapy and proper diagnostic workup of other conditions linked to the type of cancer (e.g. haematological disorders and lung dysfunction) are therefore of paramount importance for appropriate surgical decision-making. Careful evaluation of the association of cardiovascular disease to be treated and the prognosis of remitted or active cancer should be established to enhance the prediction of early, medium and long-term outcomes and for a more correctly informed patient. Furthermore, if the prognosis of operated patients appears unfavourable, then alternative therapeutic strategies can be applied without significant delay. The aim of this review is to give an overview of factors that should be considered in adult patients who are undergoing, or have undergone, treatment for oncological indications who are candidates for cardiac surgery.
INTRODUCTION
The number of adult patients recommended for a surgical operation due to heart or great vessel diseases and with either history of malignancies or active malignancies is increasing. Patient ageing, shared risk factors and improved diagnostics and therapies have meant that either in the cardiovascular or oncology settings a rise in prevalence and recognition has occurred [1] . Today, therefore, physicians are often confronted with surgical candidates who have been previously exposed to chemotherapy or radiation, whose consequences are known to affect cardiovascular structures to various extents [2] [3] [4] [5] [6] [7] [8] . Information is scarce with regard to perioperative complications associated with tumours, particularly if combined surgery for cancer and heart disease treatment is considered. Furthermore, there is limited information available regarding the effects of extracorporeal circulation on active cancer progression or dissemination [9, 10] .
The overall results of heart surgery in these patients represent an important concern and have, up till now, been poorly investigated. This is particularly due to the limited access of such patients to cardiac surgery in the past. Furthermore, although the prevalence of cardiovascular and malignant diseases has been reported to increase as a result of an ageing population [1] , the clinical implications and recommendations regarding these patients are yet to be clearly defined or remain controversial [8, [11] [12] [13] [14] .
Therefore, this article aims to review the literature on cardiovascular effects of anticancer therapy, focusing on adult cardiac surgical candidates. We provide recommendations about preoperative screening and operative strategies in these challenging candidates and shed light regarding short-, medium-and longterm post-discharge life expectancy in these patients. †The first two authors contributed equally to this work.
METHODS OF LITERATURE SEARCH
A literature search using PubMed on adult patient population (>18 years of age) was carried out. Search terms are provided in the Supplementary Material (under the section 'Methods and keywords'). This research was not intended as a systematic review but rather as an overview of available data. A summary of the most relevant articles is provided in Supplementary Material, Table S1 .
EPIDEMIOLOGY OF MALIGNANCIES IN HEART SURGERY PATIENTS
The incidence of patients with cardiovascular diseases requiring a heart operation with a history of malignancies ranges between 1.9% and 4.2% of the cardiac surgery candidates [2] . Rates in patients affected by concomitant heart and active cancer diseases range from 3.4% to 7% [1] [2] [3] [4] [11] [12] [13] [14] [15] .
The most frequent types of previously treated cancers observed in cardiac surgical individuals are related to malignancies found in specific organs, with prevalence ranging from 70% to 83% of the malignancies, with breast, colon, prostate and bladder involvement representing the most frequent tumours, each one of those representing between 10% and 22% of all tumour cases [1, 2, 15] . Types of active cancer include organ malignancies, which range from 68% to 83% of the cases, whereas haematological tumours ranged in prevalence from 7% to 17% [5, [11] [12] [13] [14] [15] .
CHEMOTHERAPY AND CARDIOVASCULAR COMPLICATIONS
The use of chemotherapeutic drugs is known to affect cardiovascular structures, but some of these adverse events are transient and, therefore, may not actually impact or jeopardize the surgical decision-making or course, unless treatment occurs simultaneously with surgery. In contrast, some agents induce permanent injury, and as such, this must be taken into account for specific potential risks in cardiac surgical candidates, even if the therapy was performed a long time prior to the surgical procedure.
As cardiotoxic effects have been widely described previously, we present a summary of the most frequently used chemotherapeutic agents, highlighting the type of cardiovascular damage, the potential mechanisms, the reversibility or irreversibility of the damage on cardiovascular structure in the Supplementary Material and in Supplementary Material, Table S2 .
PREOPERATIVE SCREENING OF CARDIAC SURGERY PATIENTS WITH A HISTORY OF CANCER OR ACTIVE CANCER
Before carrying out surgery in patients affected by malignancies, scheduled for medical (chemotherapy) or surgical treatments, a thorough evaluation of cardiac status is vital [16, 17] . As mentioned, cardiotoxicity of antineoplastic treatment and the operative surgical risk could precipitate symptomatic heart disease from a previously silent phenotype [16] .
Patients with 3 or more risk factors for cardiovascular disease or known heart disease merit specific cardiological assessment. This recommendation is in light of the common aetiological risk factors between cardiac and oncological disorders and the possible therapeutic implications [17, 18] . A multidisciplinary approach is especially advisable when an aggressive chemotherapeutic treatment is required in patients with known coronary artery disease [18] .
The cardiotoxic risk of the chemotherapeutic drug regimen should be shaped with the severity of the patient's cardiac status in mind. In particular, patients with lung cancer should be promptly screened for the presence of heart disease, before elective lung resection [19, 20] . Furthermore, in addition to routine testing, prediction of postoperative diffusing capacity to carbon monoxide (DLCO) and the maximal oxygen uptake during exercise should be considered. If a patient has a DLCO below 60% of predicted values together with a maximal oxygen uptake below 43%, then the likelihood of postoperative cardiopulmonary complications is high, and this also contraindicates resections of more than one lobe [21] .
Exercise tolerance testing and echocardiography are also effective in identifying patients at high risk for coronary problems, and patients thought to be at risk should be subjected to coronary angiography, in accordance with the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines [18] .
Therefore, the aims of the consultation are:
1. To assess the patient's cardiac condition:
• identifying the presence, type and duration of heart disease;
• verifying current treatment and efficacy;
• determining the nature and proper function of any instrumental support of heart function (pacemakers). 2. To help define the perioperative risk of major cardiovascular complications, according to the type of heart disease and the nature of surgery. 3. To help improve the anaesthesiological plan:
• suggesting a pharmacological cardio-specific treatment in preparation for surgery; • indicating appropriate intraoperative monitoring;
• considering postoperative monitoring and its duration and suggesting the most appropriate periodic instrumental inspections. 4. To support clinicians in postoperative management in case of heart destabilization or failure.
RADIATION THERAPY AND CARDIAC SURGERY
Patients undergoing cardiac surgery with previous malignancies treated with radiotherapy require a tailored preoperative diagnostic approach [16, 17] . Cardiac, vascular and pulmonary pathologies, including pericarditis, pericardial effusion, myocardial fibrosis, valvular disease (particularly aortic or mitral valve), pneumonia and lung fibrosis and limited or diffuse aortic calcification, are all potential complications of chest radiation therapy [17, 22, 23] . Furthermore, diffuse interstitial fibrosis and intimal proliferation affecting cardiac vasculature or the great vessels have also been reported [17] . Supra-aortic arch vasculopathy, resulting in injury of the carotid and subclavian arteries, is also a well-recognized complication of radiation [24, 25] . Patients at high risk for radiation-related complications are patients of a young age as well as those exposed to high radiation doses. Furthermore, higher heart volumes, concomitant cardiovascular disease risk factors and concurrent chemotherapy appear to increase the risk of complications [6] .
Patients who have previously received chest radiation show a higher operative risk than patients who are radiation-naive, and therefore, preoperative CT and echocardiography imaging is mandatory for a definitive anaesthesiological and surgical plan. This additional information offers a precise evaluation of the surgical risk [6, 26] . Radiation-related fibrosis of the internal mammary artery, for instance, may preclude its use as a graft of choice in coronary artery bypass grafting (CABG) surgery (Fig. 1) , whereas calcifications of the ascending aorta could limit its direct manipulation (i.e. cannulation and clamping) and result in alternative surgical strategies being sought (i.e. peripheral cannulation or off-pump surgery) [6] . Conversely, cardiomyopathy with severe left ventricular dysfunction implies that increased levels of support may be required, at the level of the anaesthesia and, more directly, cardiac function. This could lead to the use of continuous haemodynamic monitoring or mechanical support.
Furthermore, radiation of the neck or the abdomen may induce functional or anatomical derangement, which might have an impact on cardiac surgery procedure (Table 1) . A detailed history and consequent evaluation for concurrent abnormalities about vascular or organ dysfunction must therefore be part of preoperative screening.
CANCER THERAPY AND COAGULATION DISORDERS
Antitumoural agents have clear effects on the coagulation system. Furthermore, the presence of malignancies per se may account for a prothrombotic or pro-haemorrhagic state, regardless of the presence of a solid or haematological cancer.
As far as the thrombogenic state of patients with malignancies is concerned, it is now well acknowledged that due to compounds released from the tumour, peripheral or central thrombosis may occur. Procoagulant tissue factor appears to be the main agent responsible for a local and systemic procoagulant state [27] . Additionally, other procoagulant factors may directly activate factor X [27] .
The presence of myeloproliferative cancers, such as chronic myelogenous leukaemia, exposes the patient to higher risks of a procoagulant state and, in extreme cases, to disseminated intravascular coagulation. Deep venous thrombosis, and hence pulmonary embolism, may be the most common thrombotic complication, but arterial thrombosis-related events may also occur [28] . According to clinical conditions and symptoms
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It is, therefore, evident that some patients, particularly the ones affected by myeloproliferative disorders and undergoing cardiac surgery, may be at a higher risk for perioperative thromobotic-like complications. Antithrombotic prophylaxis with low-molecular-weight heparins is therefore recommended, although no guidelines are currently available.
The occurrence of bleeding disorders is less common than thrombosis; however, this may still represent a potential complication, mainly in patients with additional risk factors for haemorrhagic events.
SURGICAL DECISION-MAKING IN PATIENTS WITH REMITTED OR ACTIVE MALIGNANCY
In patients who have previously been treated for malignancies, the anaesthesiological and surgical strategies are well defined because the immediate preoperative period preparation is based on imaging data. This could have major implications, for example, in the context of surgical 'myocardial revascularization', the presence of a calcified ascending aorta could lead the surgeon to adopt 'off-pump' techniques. Additionally, in patients with a severe profile of comorbidities and lack of suitable graft conduits, it could lead to high-risk percutaneous coronary interventions [1] [2] [3] [4] [11] [12] [13] [14] .
In patients undergoing cardiac surgery with concomitant malignancies, anaesthesiological and surgical decision-making is more challenging, and only limited data are currently available [1] [2] [3] [4] [11] [12] [13] [14] . In this setting, simultaneous or deferred surgical excision of the tumour is an ongoing debate [29] [30] [31] [32] . The main disadvantage of a 1-stage procedure is higher bleeding risk, especially following severe surgical trauma caused by concomitant surgical incisions as would be the case, for example, in the case of gastrointestinal cancer [1] . For this reason, a dual-stage procedure is often preferable, although this would lead to a, potentially life-threatening, delay in cancer treatment. Usually, however, these patients are treated within 2 months after the cardiac procedure [33, 34] . Therefore, it is essential to keep a precise record of the patient's comorbidities. Simultaneous procedures can also increase the risk of perioperative infections such as mediastinitis, especially in patients with chronic haematological malignancies. Furthermore, myelodysplastic syndromes may alter platelet morphology, and malignant lymphomas predispose to hypercoagulability and hyper-viscosity syndromes, resulting from an acquired activated protein C resistance [35, 36] . Finally, reduction of patient stress and anxiety can be considered as an additional benefit of 1-stage procedures along with economic benefits. It seems that a 1-stage approach is beneficial in patients with heart disease and concomitant lung cancer; however, for patients with haematological and digestive tract cancers, this is not necessarily the case [2-4, 12, 13] .
Reports concerning the treatment of patients undergoing cardiac surgery and affected by concomitant 'lung cancer' are limited to a small number of case series with a relatively short follow-up. Danton et al. [30] reported on 13 patients undergoing concomitant pulmonary resection and cardiac surgery and demonstrated that the simultaneous approach can be safely performed. Adequate cancer-free survival was seen in patients with either Stage I or II pulmonary neoplastic disease but not in advanced lungs cancers (T3 stage). The same authors also reported that avoidance of cardiopulmonary bypass (CPB) is possible in selected patients, and this has led to decreased operative morbidity [30] . Ulicny et al. [37] recorded bleeding complications in 15.8% of the patients undergoing simultaneous lung resection and cardiac surgery with CPB, while Voets et al. [38] observed that sepsis was a potential related risk of the simultaneous strategy. Early extubation and CPB avoidance, when feasible, often helped to reduce the above-mentioned risks [39, 40] . In a recent systematic review, Tourmousoglou et al. [26] reported the results of combined and staged operations, concluding that lung surgery and CABG could be safely performed with adequate cancer-free survival in patients with Stage I or II lung cancer. It would be preferable to carry out lung surgery before CPB, thereby avoiding the complications of the latter. In high-risk patient groups (technically demanding cardiac procedure or unstable cardiac status), separate staged procedures (CABG as a first and lung resection as a second operation) might be the most prudent action [26] .
In patients with concomitant 'gastric cancer', partial gastrectomy is possible in low-risk patients and should be performed simultaneously along with cardiac surgery procedures [33, 34] . If a total gastrectomy is required, heart surgery should be performed initially, followed by the gastrectomy in a 2-stage procedure. In patients presenting with early gastric cancer, a gastrectomy could be performed once the patient has recovered from CABG. However, if the patient is in poor condition and the cancer is advanced, a simultaneous procedure could be required. Mediastinitis is a possible complication after a 1-stage procedure [33, 34] . Komokata et al. [33] reported data from 15 patients undergoing CABG or valvular heart surgery together with simultaneous resection of gastrointestinal malignancies. They concluded that simultaneous procedures are acceptable for patients who require dual surgery, where simple gastrointestinal resections are required, such as gastrectomy or colectomy [33] . Kamiike et al. [34] also showed promising results in terms of mortality and morbidity when simultaneous CABG and gastric surgery were performed, although careful perioperative management is vital, especially in terms of sepsis prevention [34] .
More complex is surgical decision-making in the presence of cardiac diseases and 'haematological malignancies' [35, [41] [42] [43] . CPB and surgical trauma are potent inflammatory activators with potentially adverse and severe effects on patients with haematological malignancies [36, 42, 44] . However, data on the influence of haematological malignancies on cardiac surgery are limited, although the risk of bleeding and coagulation disorders have been constantly reported [35, [41] [42] [43] . The routine use of leucocyte depletion filters and the cell-saver technique during CPB have been reported to improve the outcome in this setting, decreasing the risk of bleeding complications and haematogenous cancer dissemination [45, 46] .
POSTOPERATIVE MANAGEMENT
Patients with concomitant malignancy or a history of malignancy undergoing cardiac surgery have a higher rate of postoperative complications [1] [2] [3] [4] [11] [12] [13] [14] . Atrial fibrillation following surgery has been reported in half of the patients with malignancies [47] [48] [49] compared with 30-50% in the total population [50] . Possible reasons for this increased risk include autonomic dysfunction or increased inflammation. The use of amiodarone in patients with lung cancer should be carefully balanced against its known side effects on the lungs, such as acute respiratory distress syndrome [49] . Pulmonary embolism and other embolic events are also well-known postoperative complications due to the typical hypercoagulable state of these patients [14, 51] . The expression of tumour tissue factors, the direct antiplatelet activation and the associated hyper-viscosity syndromes are potential causative factors for the observed higher rates of venous thromboembolisms and pulmonary embolism [14, 51] . Haemorrhagical complications, especially in patients with haematological malignancies, deserve a careful approach to minimize perioperative bleeding and surgical trauma [1, 4, 52] . Blood transfusion requirements are, however, the most commonly observed complications in patients with concomitant cardiac and cancer diseases and occur in more than 80% of the operated patients [14] . The high rate of transfusion rate also could account for the encountered higher rate of respiratory complications, prolonged ventilation, pneumonia, risk of mediastinitis and sepsis in the patient setting [1] [2] [3] [4] [11] [12] [13] [14] .
THE EFFECTS OF EXTRACORPOREAL CIRCULATION ON TUMOUR RECURRENCE OR PROGRESSION
One of the major surgical concerns in approaching patients with concomitant cardiac and cancer diseases is the use of CPB [15] . Both in vitro and in vivo studies have demonstrated that the operative stress and CPB use induces suppression of the immune system. Increased levels of IL-10 and TGF-b inhibit T cell regulation, macrophage and natural killer cell activity have all been reported. However, the relationship between the use of CPB and cancer progression has not yet been clearly demonstrated, either in the early postoperative period or in long-term outcomes [57] . Furthermore, only a few studies have actually analysed the impact of CPB on cancer progression [15, [53] [54] [55] [56] . Vieira et al. [25] investigated the association of cardiac and non-cardiac mortality following CABG with CPB and non-surgical interventions. When compared with non-surgical patients, patients undergoing CABG performed with CPB was associated with a lower incidence of cardiac death (77% vs 47%) and a higher incidence of noncardiac mortality, especially related to cancer (21% vs 7%). However, Schoenmakers et al. [58] reported no significant differences in early and late results in a comparison between on-pump and off-pump CABG and lung resection. Similarly, Suzuki et al.
[10] demonstrated no significant adverse effects of CPB on cancer progression during a 5-year follow-up, with Nardi et al. [15] showing similar findings. In this study, however, there appeared to be a larger operative risk when haematological malignancies were present [15] .
Potapov et al. [59] specifically looked at the impact of cardiac surgery using CPB on chronic lymphatic leukaemia progression. Cardiac surgery using CPB did not have a negative impact on the natural course of chronic lymphatic leukaemia. These data demonstrated an increase in chemotherapy-free survival time and reduced postoperative chemotherapy administrations [59] . Although evidence is scarce, cardiac surgery using CPB does not seem to promote malignancy progression or to increase longterm mortality.
Finally, it should be underlined that the current surgical scores (EuroSCORE and STS scores) do not take into account cancer disease status in their calculations [60, 61] . This is despite the impact that cancer appears to have on the postoperative outcomes of patients undergoing simultaneous cardiac surgery [1] [2] [3] [4] [11] [12] [13] [14] .
EARLY AND LATE OUTCOMES
Patients undergoing cardiac surgery with a history of malignancy generally do not have an increased risk of early mortality but do have an increased risk of morbidity [1] [2] [3] [4] [11] [12] [13] [14] . Chan et al. [14] compared matched patients undergoing cardiac surgery with (n = 83) and without (n = 216) a history of malignancy. In this study, there were no observed differences in hospital mortality. However, patients with a history of malignancy experienced a higher rate of blood transfusion (80% vs 49%), postoperative AF (42.2% vs 33.8%), cerebrovascular accidents (2.4% vs 0%), pneumonia (14.5% vs 6%), reintubation rate (8.4% vs 0.9%) and sepsis (8.4% vs 1.9%).
Patients with concomitant cardiac and cancer diseases present a hospital mortality rate of 0-20.8% in combined procedures and 0-10% in the staged ones [14] . Interestingly, no differences have been reported in in-hospital mortality or morbidity between patients undergoing cardiac and concomitant cancer surgery [1] . Patients with haematological malignancies present with higher hospital mortality rates, ranging from 14.3% to 18.7% [14, 59] .
When considering the long-term follow-up of these patients, there is conflicting information. For example, Carrascal et al. [11] showed that postoperative survival is strictly related to the preoperative left ventricular function and the presence of chronic pulmonary disease, as well as the time between cancer diagnosis and surgery. This was confirmed by Mistiaen et al. [13] who showed that the presence of a malignant tumour was the dominant independent predictor for survival after cardiac surgery. They also showed that mortality was mainly due to progression of the primary malignancy, with almost 50% of deaths due to this reason [13] . This was especially true when there was a short interval between cancer diagnosis and cardiac surgery operation [13] .
CONCLUSIONS
An ageing population and shared risks factors are the most likely causes for increases in the incidence of patients undergoing cardiac surgery previously treated for malignancies or with active cancer. The combination of the 2 diseases poses several issues in cardiac surgical candidates, which need to be considered carefully and can be summarized as follows:
1. A detailed tumour-related history is mandatory to understand whether these conditions may impact cardiovascular structures, as well as surgical planning, and postoperative outcome. Treatment, or tumour type, particularly if active, may increase operative risk, impair myocardial or vascular structure that are to be repaired or replaced or may generate a prothrombotic or pro-haemorrhagic state. 2. Based on the previous therapy and patient history, a careful diagnostic workup, subsequent preoperative planning and evaluation of risk/benefit surgery are critical. 3. Although conclusive/comprehensive information is currently lacking, it appears that extracorporeal circulation neither increases the aggresiveness or early/late recurrence of previously treated malignancies nor reduces the chances of cure for an active cancer. 4. Particular attention is required with regard to coagulation disorders and ad hoc prophylaxis and monitoring may be required. 5. Several combinations, such as active lung cancer and cardiac surgery requiring concomitant surgery, show unfavourable medium-and long-term results, indicating that extra care should be taken in the decision-making and in patient selection. 6. Cancer status needs to be taken into account when assessing medium-and long-term results.
Taking all of these factors into account should ensure that adult cancer patients receive the best possible care and treatment when cardiac surgery is necessary.
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